Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology industry, specializing in the development of essential biological reagents and supplements that facilitate advancements in life sciences research and biomanufacturing. The company's innovative offerings are integral to high-demand sectors, including vaccine development, cell and gene therapy, and diagnostic testing, underscoring its commitment to quality and superior customer support. With a robust biotechnology foundation and a focus on innovation, Alpha Teknova is well-positioned to capitalize on growth opportunities within the rapidly evolving life sciences market, enhancing its appeal to institutional investors seeking strategic investments.
| Revenue (TTM) | $43.70M |
| Gross Profit (TTM) | $15.12M |
| EBITDA | $-8.97M |
| Operating Margin | -23.70% |
| Return on Equity | -24.20% |
| Return on Assets | -9.28% |
| Revenue/Share (TTM) | $0.82 |
| Book Value | $1.28 |
| Price-to-Book | 6.25 |
| Price-to-Sales (TTM) | 8.87 |
| EV/Revenue | 9.18 |
| EV/EBITDA | -6.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 18.50% |
| Shares Outstanding | $53.69M |
| Float | $10.99M |
| % Insiders | 9.31% |
| % Institutions | 87.31% |
Volatility is currently expanding
The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Alpha Teknova NASDAQ: TKNO reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company's 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half of 2026.
HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched Build-Tek™, an AI-powered custom order configurator that enables developers of therapies and diagnostics to design complex custom products and submit a request for quote in minutes.
HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market.
Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript
First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, following the close of market.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TKNO and any ticker you trade — then tracks every position and per-strategy win rate.
